MOBX vs TVRD Comparison

Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.